Acadia Pharmaceuticals
Pharmaceutical company, which developed Nuplazid, based in San Diego, California.
ACAD Nasdaq
ISIN US0042251084 SEC CIK 1070494
Follow Acadia Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$342.3M
+22.8% vs same quarter last year
Net income
$53.5M
−25.4% vs same quarter last year
EPS, diluted
$0.31
−26.2% vs same quarter last year
Operating cash flow
$11.5M
−84.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $1.1B | $391M |
| FY24 | $957.8M | $226M |
| FY23 | $726.4M | −$61M |
| FY22 | $517.2M | −$214M |
| FY21 | $484.1M | −$168M |
| FY20 | $441.8M | −$281.6M |
| FY19 | $339.1M | −$235.3M |
| FY18 | $223.8M | −$245.2M |
| FY17 | $124.9M | −$289.4M |
| FY16 | $17.3M | −$271.4M |
| FY15 | $61K | −$164.4M |
| FY14 | $120K | −$92.5M |
| FY13 | $1.1M | −$37.9M |
| FY12 | $4.9M | −$20.8M |
| FY11 | $2.1M | −$22.8M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 91.7% | 9.8% | 36.5% |
| FY24 | 91.5% | 24.1% | 23.6% |
| FY23 | 94.3% | −10.1% | −8.4% |
| FY22 | 98% | −43.2% | −41.4% |
| FY21 | 97.8% | −35.2% | −34.7% |
| FY20 | 97.7% | −64.9% | −63.7% |
| FY19 | 96.7% | −72.7% | −69.4% |
| FY18 | 94.5% | −110.6% | −109.6% |
| FY17 | 92.7% | −234.1% | −231.7% |
| FY16 | 82.2% | −1574.1% | −1565.9% |
| FY15 | - | −269855.7% | −269578.7% |
| FY14 | - | −77691.7% | −77062.5% |
| FY13 | - | −3344.7% | −3314.2% |
| FY12 | - | −425.6% | −424.9% |
| FY11 | - | −1105.6% | −1101.4% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $105.1M |
| FY24 | $157.2M |
| FY23 | $16.7M |
| FY22 | −$114M |
| FY21 | −$126.8M |
| FY20 | −$143.8M |
| FY19 | −$152.3M |
| FY18 | −$169.6M |
| FY17 | −$218.6M |
| FY16 | −$209.9M |
| FY15 | −$123.9M |
| FY14 | −$66.6M |
| FY13 | −$32.4M |
| FY12 | - |
| FY11 | −$19.9M |
- Acadia Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Acadia Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | 36.5% | −30.6% |
| FY24 | 23.6% | −47% |
| FY23 | −8.4% | −58% |
| FY22 | −41.4% | −80.4% |
| FY21 | −34.7% | −71.9% |
| FY20 | −63.7% | −62.2% |
| FY19 | −69.4% | −46.3% |
| FY18 | −109.6% | −49.6% |
| FY17 | −231.7% | −45.9% |
| FY16 | −1565.9% | −36% |
| FY15 | −269578.7% | −38.4% |
| FY14 | −77062.5% | −35.5% |
| FY13 | −3314.2% | −37.1% |
| FY12 | −424.9% | −29.1% |
| FY11 | −1101.4% | −27.9% |